Editor’s Note
**Editor’s Note:** Hugel has introduced TheChaeum Signature, a new HA filler designed to improve safety by reducing cross-linking agents. The four-product lineup offers tailored options for medical professionals, reflecting the company’s ongoing R&D efforts to strengthen its filler portfolio.
Hugel announced on the 20th that it has launched a new hyaluronic acid (HA) filler product, ‘TheChaeum Signature’, which enhances safety by minimizing the use of cross-linking agents.
TheChaeum Signature is a product line that embodies Hugel’s R&D achievements aimed at advancing the competitiveness of its HA filler lineup. It consists of four products with a broad spectrum of physical properties, allowing medical professionals to choose based on the treatment area and purpose.
Typically, HA fillers undergo a cross-linking process to maintain hyaluronic acid, which is easily degraded in the body, in a stable gel form. TheChaeum Signature applies the ‘MPC method’, a proprietary technology of affiliate ‘Across’, reducing the amount of cross-linking agent used by over 50% compared to conventional manufacturing processes, while maximizing cross-linking efficiency through a special process using high-concentration HA raw materials.
Another feature is that through a multi-purification process lasting about two weeks—longer than standard manufacturing processes—it significantly reduces residual cross-linking agent (BDDE) as well as micro-hydrolysis byproducts (BDPE) that may arise during the cross-linking stage, thereby enhancing safety and quality.
Despite minimizing the use of cross-linking agents, it maintains the firm physical properties and durability that were the strengths of the existing ‘TheChaeum Premium’ line.
